ÂÜÀòÂÒÂ×

David joined Sona Nanotech as a consultant in the spring of 2020 to provide strategic advisory with respect to its commercialization and capital markets strategies as the company plotted a path toward developing and taking its COVID-19 test to market. In July of 2020, he was named CEO with the mandate to secure third-party evaluations of the test, manufacturing capacity via contract manufacturing organizations, regulatory approvals and, ultimately, sales.

He has 25 years of experience in finance, international business, innovation, M&A, and capital markets. He has previously led corporate strategy and M&A function at a dual-listed public company, been an innovation consultant, and provided financial advisory services.